CytomX Therapeutics (CTMX) Price & Analysis

Compare

877 Followers

CTMX Stock Chart & Stats

$4.26

-$0.06(-5.83%)

At close: Jan 08 4:00 PM EST

$4.26

-$0.06(-5.83%)

Day’s Range― - ―

52-Week Range$0.40 - $4.66

Previous CloseN/A

Volume1.08M

Average Volume (3M)2.31M

Market Cap

$728.57M

Enterprise Value$388.33M

Total Cash (Recent Filing)$143.63M

Total Debt (Recent Filing)$5.60M

Price to Earnings (P/E)10.2

Beta2.81

Next Earnings

Mar 04, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding169,435,400

10 Day Avg. Volume1,393,886

30 Day Avg. Volume2,311,632

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-190.73

Price to Sales (P/S)0.63

P/FCF Ratio-1.00

Enterprise Value/Market Cap0.53

Enterprise Value/Revenue3.42

Enterprise Value/Gross Profit3.42

Enterprise Value/Ebitda14.87

Forecast

1Y Price Target

$7.10

Price Target Upside66.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy SignalEarly trial results show a higher confirmed tumor response rate and longer progression-free survival than current late-line colorectal cancer therapies in initial efficacy-evaluable patients, indicating potential to change treatment practice if replicated.

Dose-dependent Efficacy PotentialA notably higher confirmed response rate at the highest tested dose suggests a dose-dependent efficacy profile that could be used to optimize benefit while guiding dosing strategy.

Enrollment And Trial SizeEnrollment expansion to around 100 patients in the Phase 1 trial is expected to strengthen the evidence base and provide clearer insights into efficacy and the path toward regulatory approval.

Bears Say

Analyst Caution And De-risking NeedsAnalyst neutral ratings reflect the need for more de-risking data, suggesting market confidence may remain muted until more mature safety and efficacy results are available.

Downside Efficacy RiskAn outcome with low response rates and brief disease control would fail to differentiate from existing late-line options and would likely dampen investor enthusiasm.

Serious Safety EventA reported treatment-related fatal acute kidney injury raises safety concerns that may prompt closer regulatory scrutiny and could slow development progress.

CytomX Therapeutics News

CytomX Therapeutics announces business update, 2026 milestones

CytomX Therapeutics (CTMX) announced a business update and anticipated milestones for 2026. Clinical Program Updates and 2026 Milestones:...

1d ago

CTMX

CytomX Therapeutics: Asymmetric Upside Ahead of Pivotal CX-2051 Colorectal Cancer Data Supports Reiterated Buy and $10 Target

CytomX Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from...

13h ago

CTMX

Buy Rating for CytomX Therapeutics’ CX-2051 Based on Promising Colorectal Cancer Treatment Potential

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on CytomX Therapeutics, with...

1M ago

CTMX

CytomX Therapeutics price target raised to $10 from $5 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on CytomX Therapeutics (CTMX) to $10 from $5...

2M ago

CTMX

CytomX Therapeutics price target raised to $6.50 from $5 at Piper Sandler

Piper Sandler raised the firm’s price target on CytomX Therapeutics (CTMX) to $6.50 from $5 and keeps an...

2M ago

CTMX

CytomX Therapeutics Earnings Call Highlights Clinical Progress

CytomX Therapeutics Inc. (($CTMX)) has held its Q3 earnings call. Read on for the main highlights of the...

2M ago

CTMX

CytomX Therapeutics Reports Q3 2025 Financial Results

CytomX Therapeutics Inc. ( ($CTMX) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

CTMX

CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)

Reports Q3 revenue $5.96M, consensus $11.5M. “CytomX continued to execute against its pipeline priorities this quarter, highlighted by...

2M ago

CTMX

CytomX Therapeutics Advances CX-2051 Study in Solid Tumors

CytomX Therapeutics Inc. (($CTMX)) announced an update on their ongoing clinical study. Study Overview: CytomX Therapeutics Inc. is...

2M ago

CTMX

Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051

J.P. Morgan analyst Anupam Rama has maintained their neutral stance on CTMX stock, giving a Hold rating on...

2M ago

CTMX

CytomX Therapeutics management to meet with Oppenheimer

Meeting to be held on October 23-24 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

3M ago

CTMX

CytomX Therapeutics price target raised to $6 from $3.50 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on CytomX Therapeutics (CTMX) to $6 from $3.50 and...

3M ago

CTMX

CytomX Therapeutics appoints Rachael Lester as chief business officer

CytomX Therapeutics (CTMX) announced the appointment of Rachael Lester as senior VP, chief business officer. In this role,...

3M ago

CTMX

Oppenheimer positive on CytomX after Merus colon cancer data

Oppenheimer says Merus’ (MRUS) colon cancer data update reinforces its “enthusiasm” for CytomX Therapeutics’ (CTMX) dose expansion data....

3M ago

CTMX

MRUS

CTMX FAQ

What was CytomX Therapeutics Inc’s price range in the past 12 months?

CytomX Therapeutics Inc lowest stock price was $0.40 and its highest was $4.66 in the past 12 months.

What is CytomX Therapeutics Inc’s market cap?

CytomX Therapeutics Inc’s market cap is $728.57M.

When is CytomX Therapeutics Inc’s upcoming earnings report date?

CytomX Therapeutics Inc’s upcoming earnings report date is Mar 04, 2026 which is in 53 days.

How were CytomX Therapeutics Inc’s earnings last quarter?

CytomX Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.049 by -$0.041.

Is CytomX Therapeutics Inc overvalued?

According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CytomX Therapeutics Inc pay dividends?

CytomX Therapeutics Inc does not currently pay dividends.

What is CytomX Therapeutics Inc’s EPS estimate?

CytomX Therapeutics Inc’s EPS estimate is -0.09.

How many shares outstanding does CytomX Therapeutics Inc have?

CytomX Therapeutics Inc has 169,435,400 shares outstanding.

What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?

CytomX Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.049. Following the earnings report the stock price went down -13.604%.

Which hedge fund is a major shareholder of CytomX Therapeutics Inc?

Currently, no hedge funds are holding shares in CTMX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CytomX Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

66.76%

Trailing 12-Months

Asset Growth

13.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics (CTMX) Earnings & Revenues

Historic Earnings Reports

CTMX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive overall sentiment with strong clinical progress and strategic advancements in key programs, despite a decrease in revenue and some adverse events in trials.View all CTMX earnings summaries

CTMX Stock 12 Month Forecast

Average Price Target

$7.10

▲(66.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.729230769230769,5.168461538461538,5.607692307692307,6.046923076923077,6.4861538461538455,6.9253846153846155,7.364615384615385,7.803846153846154,8.243076923076924,8.682307692307692,9.12153846153846,9.560769230769232,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.506153846153846,4.722307692307692,4.938461538461539,5.154615384615385,5.3707692307692305,5.586923076923076,5.803076923076922,6.019230769230769,6.235384615384615,6.451538461538461,6.667692307692308,6.883846153846154,{"y":7.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.29,4.421538461538462,4.553076923076923,4.684615384615385,4.8161538461538465,4.947692307692308,5.07923076923077,5.21076923076923,5.342307692307692,5.473846153846154,5.605384615384615,5.736923076923077,5.868461538461538,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >